Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
OwnerStacy Plum, Steven Strawn +4inventors
InventorsStacy Plum, Steven Strawn, Theresa LaVallee, Carolyn Sidor, William Fogler, Anthony Treston
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to methods and compositions of treating disease characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering antiangiogenic agents in combination with chemotherapeutic agents. More specifically, the present invention relates to a methods and compositions of treating diseases characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering 2-methoxyestradiol, in combination with chemotherapeutic agents.
Claims55
A method of treating diseases associated with undesirable and/or excessive angiogenesis and/or undesirable cell proliferation comprising administering simultaneously to an animal or human;
- a) a first composition comprising a therapeutic agent selected from one or more of the following;
- wherein Ra is selected from —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CCCH3, —CHCH—CH3, or CH2—CHCH2 and a pharmaceutically acceptable carrier, diluent, or excipient;
- and
- b) and one or more anti-cancer agents.
A method for treating diseases associated with undesirable and/or excessive angiogenesis and/or undesirable cell proliferation comprising administering sequentially to an animal or human;
- a) a first composition comprising, a therapeutic agent selected from one or more of the following
- wherein Ra is selected from —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CCCH3, —CHCH—CH3, or CH2—CHCH2 and a pharmaceutically acceptable carrier, diluent, or excipient;
- and
- b) a second composition comprising one or more anti-cancer agents.
A composition for treating diseases associated with undesirable and/or excessive angiogenesis and/or undesirable cell proliferation comprising;
- a) a compound selected from one or more of the following;
- wherein Ra is selected from —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CCCH3, —CHCH—CH3, or CH2—CHCH2;
- b) one or more anti-cancer agents;
- and
- c) a pharmaceutically acceptable carrier, diluent, or excipient.
Dependencies are inferred from the claim text.